Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis

American Journal of Medicine

Volumn 103, Issue 4, 1997, Pages 298-307

  Thiebaud D ^a   Burckhardt, P ^a   Kriegbaum, H ^b   Huss, H ^b   Mulder, H ^c   Juttmann, J R ^d   Schoter K H ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c Researchcentrum Good Clin Practice   (Netherlands)

^d CPRLab   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; CREATININE; DEOXYPYRIDINOLINE; IBANDRONIC ACID; OSTEOCALCIN; PARATHYROID HORMONE; PYRIDINOLINE;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MINERAL; CARCINOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; FOREARM; HEADACHE; HIP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEG CRAMP; LUMBAR SPINE; MAJOR CLINICAL STUDY; MIGRAINE; OSTEOLYSIS; OUTPATIENT CARE; PAIN; PATIENT COMPLIANCE; PNEUMONIA; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

BONE DENSITY; BONE RESORPTION; DENSITOMETRY, X-RAY; DIPHOSPHONATES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 0141533811     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(97)00249-0     Document Type: Article

References (28)

1. Consensus development Conference: diagnosis, prophylaxis and treatment of osteoporosis. Am J Med. 1993;94:646-650.
2. Riggs BL, Melton LJ III. The prevention and treatment of osteoporosis. NEJM. 1992;327:620-627.
3. Fleisch H. Bisphosphonates: pharmacology and use in the treatment of tumor-induced hypercalcaemia and metastatic bone disease. Drugs. 1991; 42:919-944.
4. Storm T, Thamsborg G, Steiniche T. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. NEJM. 1990;322:1265-1271.
5. Watts NB, Harris ST, Genant HK. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. NEJM. 1990;323:73-79.
6. Harris ST, Gertz BJ, Genant HK. The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodelling in early postmenopausal women. J Clin Endocrinol Metab. 1993;76:1399-1406.
7. Chesnut CH, McClung MR, Ensrud KE. Alendronate treatment of postmenopausal osteoporotic women: Effect of multiple dosages on bone mass and bone remodelling. Am J Med. 1995;99:144-152.
8. Papapoulos SE. The role of bisphosphonates in the prevention and treatment of osteoporosis. Am J Med. 1993;95(suppl 5A):48S-52S.
9. Gertz BJ, Holland SD, Kline WF. Clinical pharmacology of alendronate sodium. Osteoporosis Int. 1993;3(suppl 3):13-16.
10. Lufkin EG, Argueta R, Whitaker MD. Pamidronate: An unrecognized problem in gastrointestinal tolerability. Osteoporosis Int. 1994;4:320-322.
11. Passeri M, Baroni MC, Pedrazzoni M. Intermittent treatment with intravenous 4-amino-1-hydroxybutylidene-1, 1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis. Bone Mineral. 1991;15:237-248.
12. Thiébaud D, Burckhardt P, Melchior J. Two years effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occuring in the menopause. Osteoporosis Int. 1994;4:76-83.
13. Muhlbauer RC, Bauss F, Fleisch H. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res. 1991;6:1003-1010.
14. Monier-Faugere MC, Friedler RM, Bauss F, Malluche H. A new bisphosphonate, BM 21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs. J Bone Miner Res. 1993;8:1345-1355.
15. Fleisch H. The bisphosphonate ibandronate, given daily as well as discontinuously, decreases bone resorption and increases calcium retention as assessed by Ca kinetics in the intact rat. Osteoporosis Int. 1996;6:166-170.
16. Pecherstorfer M, Herrmann Z, Body JJ, Thiébaud D. Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J Clin Oncology. 1996;14:268-276.
17. Pecherstorfer M, Buck S, Huss HJ, Body JJ. Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection. J Bone Miner Res. 1996;11:587-593.
18. Steiger P, Wahner HW. Instruments using fan-beam geometry. In Wahner HW, Fogelman I, eds. The Evaluation of Osteoporosis: Dual Energy X-Ray Absorptiometry in Clinical Practice. London: Martin Dunitz Ltd.: 1994;75-87.
19. Garnero P, Grimaux M, Demiaux B, Delmas PD. Measurement of serum osteocalcin with a human-specific two-site radioimmunoassay. J Bone Miner Res. 1992;7:1389-1397.
20. Bonde M, Qvist P, Riis BJ, Christiansen C. Immunoassay for quantifying type I collagen degradation products in urine. Clin Chem. 1994;40:2022-2025.
21. Hanson DA, Weis MAE, Bollen AM, Eyre DR. A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross linked N-telopeptides in urine. J Bone Miner Res. 1992;7:1251-1258.
22. Uebelhart D, Gineyts E, Chapuy MC, Delmas PD. Urinary excretion of pyridinium cross-links: a new marker of bone resorption in metabolic bone disease. Bone Miner. 1990;8:87-96.
23. Garnero P, Weichung JS, Gineyts E, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab. 1994;79:1693-1700.
24. Seibel MJ, Cosman F, Robins SP, Riggs BL. Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis. J Bone Miner Res. 1993;8: 881-889.
25. Garnero P, Gineyts E, Riou JP, Delmas PD. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab. 1994;79:780-785.
26. Christiansen C. Prevention and treatment of osteoporosis: review of current modalities. Bone. 1992;13(Suppl 1):35-39.
27. Gertz BJ, Holland SH, Kline WF. Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther. 1995;58:288-298.
28. de Groen PC, Lubbe DF, Hirsch LJ. Esophagitis associated with the use of alendronate. NEJM. 1996;335:1016-1021.